Concurrent AV-ATP Pacing for Tachyarrhythmia Termination
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cardiac rhythm management systems face limitations in effectively terminating tachyarrhythmias using anti-tachycardia pacing (ATP) due to its ineffectiveness in certain types of arrhythmias and the high energy consumption and patient discomfort associated with cardioversion/defibrillation therapies.
Innovation Solution
An implantable medical device that delivers anti-tachyarrhythmia therapies, including concurrent atrio-ventricular ATP modes, which synchronize or independently time atrial and ventricular pacing pulses to effectively treat tachyarrhythmias by selecting appropriate ATP modes based on the characteristics of the detected arrhythmia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If concurrent atrio-ventricular ATP mode is used to treat tachyarrhythmias involving both chambers, then therapy efficacy is improved, but device complexity increases
Solution Approach 1:
The patent combines atrial and ventricular ATP delivery into a single concurrent AV-ATP mode, merging two separate pacing functions into one integrated therapy that can simultaneously address reentrant circuits involving both atrial and ventricular chambers
Solution Approach 2:
The ICD is designed with multi-functional ATP capability that can adaptively switch between A-ATP, V-ATP, and concurrent AV-ATP modes based on the detected arrhythmia characteristics, making the device universally effective against different types of tachyarrhythmias
2Reliability
If cardioversion/defibrillation is used to terminate tachyarrhythmia, then therapy effectiveness is improved, but energy consumption increases and patient discomfort worsens
Solution Approach 1:
The system performs preliminary ATP therapy before resorting to cardioversion/defibrillation, attempting to terminate the tachyarrhythmia with lower-energy pacing pulses first, and only escalating to high-energy shocks if ATP fails, thereby reducing overall energy consumption and patient discomfort
Solution Approach 2:
The patent changes the therapy parameter from high-energy cardioversion/defibrillation pulses to lower-energy ATP pacing pulses, adjusting the energy level according to the specific arrhythmia type and treatment progression, thereby reducing energy consumption while maintaining effectiveness
3Device complexity
If single-chamber ATP mode is used, then device simplicity is maintained, but therapy efficacy deteriorates when reentrant circuit involves both chambers
Solution Approach 1:
The patent implements a dynamic ATP delivery system that can adaptively switch between A-ATP, V-ATP, and concurrent AV-ATP modes based on real-time detection of arrhythmia characteristics, allowing the therapy to evolve from simple to complex as needed rather than being fixed at one level
Data Source
AI summary
An implantable medical device delivers anti-tachyarrhythmia therapies including anti-tachycardia pacing (ATP). If a detected tachyarrhythmia is classified as a type suitable for treatment using ATP, the implantable medical device selects one of an atrial ATP (A-ATP) mode, a ventricular ATP (V-ATP) mode, and a concurrent atrio-ventricular ATP (concurrent AV-ATP) mode according to the characteristics of the detected tachyarrhythmia. The concurrent ATP mode is an ATP mode during which the atrial pacing pulses and the ventricular pacing pulses are delivered concurrently. In one embodiment, the concurrent AV-ATP mode includes a synchronized atrio-ventricular ATP (synchronized AV-ATP) mode during which atrial and ventricular pacing pulses are delivered synchronously and an independent atrio-ventricular ATP (independent AV-ATP) mode during which atrial and ventricular pacing pulses are delivered concurrently but timed independently.